glp 1 agonists diabetes GLP-1 - What is it? Dual GIP/GLP-1 receptor agonists: New

Gold SL, Raman M, Sands BE, Ungaro R, Sabino J

a higher 2.4 mg dose in comparison with matched placebos over 68 weeks in 1210 participants (2)

For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80

There are emerging/established benefits for cardiovascular disease, heart failure, chronic kidney disease, sleep apnoea, osteoarthritis, and metabolic-associated steatotic liver disease [8]

The insulin resistance in T2DM and NAFLD determines an increase in hepatic production and reduced muscle glucose uptake, as well as lowering lipolysis in adipose tissue and increasing hepatic lipogenesis, consequently raising glucose and circulating free fatty acids (FFAs) levels [5]

GLP-1 is a multifaceted peptide that can modulate alcohol-related responses